統合腫瘍学ジャーナル

There are two major hypotheses that explain the mechanism of tumor progression from in situ to stromal tumor invasion. One is proteolytic enzymes theory which is based on the overproduction of MMPs by the myoepithelial cells and surrounding tumor cells and the other theory is known as focal myoepithelial cell layer disruption (FMCLD theory). Proteolytic enzymes theory???In order to invade the stroma and metastasize, tumor cells have to cross several barriers like BM, myoepithelial cell layer, interstitial tissues and extracellular matrices, which are composed primarily of collagen, proteoglycans, laminin, elastin, and other glycoproteins. Tumor cells over- express and secrete proteases which are capable of degrading the components of these barriers and thus facilitate their migration. According to the proteolytic enzyme theory, the progression from the in situ to invasive stage is believed to be triggered by the overproduction of various proteolytic enzymes by the tumor cells, such as MMPs, serine proteases and cathepsins resulting in the degradation of the BM. Focal myoepithelial cell layer disruption (FMCLD) theory???recently, a new model of tumor invasion of stroma by the epithelial cells was proposed by Yan Man. According to this model, tumor invasion is triggered by a series of events which begin when the myoepithelial cells are damaged by any genetic abnormalities, inflammation, mutations, localized trauma or other physical/chemical injuries which result in the disruption of the myoepithelial cell layer or impairs the normal replacement process. In fact, it is now known that disruption in the myoepithelial cell layer is the most distinct sign of tumor invasion in breast cancer. FMCLD theory has some advantages over proteolytic theory because it focuses on the interaction of the different types of cells present in the tumor microenvironment. Focal breakdown of myoepithelial cell layer and BM at sites of white blood cell infiltration have also been observed in DCIS. Emphasizing the necessity of changes in both in ???seed??? and ???soil??? for progression, epithelial cell clusters overlying the disrupted myoepithelial layers were different from adjacent cells within the same duct with respect of ER (estrogen receptor) status, frequency or pattern of LOH and/or MSI, and expression of tumor progression related genes, normal stem cell and proliferation markers, and showed invasion into the stroma and blood vessels-like structures. Since tumor-stromal interactions are bi-directional, identification of the initiating events requires further study.
 

Tumors of the paranasal sinuses include a wide spectrum of pathologic conditions with variety of presentations and prognosis. Despite surgical excision, local recurrence is high. Recent progresses in the treatment of nasal and paranasal sinus tumors have evolved to the minimally invasive endoscopic surgery as the exclusive management for most cases of benign tumors and as a hybrid method in most cases of malignant tumors. In endoscopic hybrid group, the endoscope entered liberally through the open accesses to give the maximum view and reduce recurrences. In this presentation, endonasal endoscopic surgery for sinonasal neoplasms will be discussed, emphasizing advantages, disadvantages and recent advances in this field. Endoscopic surgical resection could enhance complete tumor removal by providing excellent magnified and angled view, with or without complementary approaches. It could be accomplished not only by endonasal routes, but also as hybrid with open approached to enhance the accuracy and vision. Image guided surgery could help to make a safe surgery with more confidence in tumor removal.
 

Breast cancer makes up approximately 25% of all newly diagnosed cancers in women globally and is the second most common cancer in the world today. With the rates of newly diagnosed cancer cases, increasing globally and cancer being amongst the world???s leading cause of death, the question arises, what must the global community do to win the fight against cancer? In order to tackle the issue at hand, the field of oncology care is rapidly evolving with many organizations and institutions investing heavily in various advancing technologies and treatment modalities. With the availability of knowledge and information on different treatment modalities readily available online, many patients are well informed of the treatment options available. However, not all cancer centers are able to provide the most up to date treatment due to financial constraints and often times lack of expertise in niche treatment deliveries. Our industry has reached a point of inflection and the need for integrated collaboration across facilities is more important today than it has ever been. The issue for many facilities is the fear of loss of revenue to competing centers and the lack of ability to invest in the ever-evolving treatment modalities, which can lead to sub-optimal clinical outcomes for the patients. This presentation focuses on the need for integrated collaboration and the importance of working together across facilities as opposed to competing against one another. The discussion centers around three key areas are: (1) Understanding the various treatment modalities, (2) fostering an environment for each group of physicians and their specialties, and (3) building an integrated care network. The various successful models that have been implemented in order to ensure the best clinical outcomes for the patients, giving them access to the latest cutting edge treatment throughout the world will be a part of the presentation.
 

After the successful completion of several “Cancer Research”, the Conference series is glad to include another international conference in the series. The conference is tilted as “International Conference on Cancer Treatment and Prevention” the conference will be held on December 14-15, 2020 at Tokyo, Japan. This 2020 Cancer Treatment and Prevention Conference will give you exemplary experience and great insights in the field of research. Cancer is the second leading cause of death worldwide. It’s crucial to remember that cancer is not one disease – it’s more than 200 cancer diseases involved. All different, unique diseases, which  require different approaches for treatment. Treatments that work for some cancers don’t work for others and sometimes those treatments simply stop working. Only worldwide research will enhance our understanding of cancer and help us find and develop better, more effective treatments. And only a global search for answers will help us get to grips with this disease. . The conference will provide with an exceptional opportunity for the delegates from Universities and Institutes to interact with the world class Scientists and Industry Professionals working in the field of cancer (or) oncology

We are satisfied to invite you to the " International Conference on Cancer Treatment and Prevention" after the fruitful culmination of the arrangement of Cancer Research Congress. The congress is booked to occur in the excellent city of Tokyo, Japan on December 14-15, 2020. This Cancer Treatment discussion 2020 gathering will give you a model research understanding and gigantic thoughts. The point of view of the Cancer Treatment and Prevention Conference 2020 is to set up new research to assist individuals with seeing how new procedures have progressed and how the field has created lately. Malignant growth Treatment Forum 2020 will join world-class teachers, researchers, specialists, understudies, Perfusionists, Oncologists to examine approach for infirmity remediation for Cancer illnesses, Breast Cancer and wellbeing issue. Malignant growth Treatment Forum 2020 are wanted to give different data that will keep accommodating authorities beside one another of the issues affecting the desires, finding and treatment of Cancer infections. The gathering of this occasion will be managed around the subject "Malignant growth Treatment Forum 2020". 

Worldwide, one in eight deaths is due to cancer. Projections based on the GLOBOCAN 2012 estimates predict a substantive increase new cancer cases per year by 2035 in developing countries if preventive measures are not widely applied. According to the World Health Organization (WHO), millions of lives could be saved each year if countries made use of existing knowledge and the best cost-effective methods to prevent and treat cancer. Therefore, the aim of this study is to estimate a provisional budget against cancer in low and middle incomes countries, according the GNI-PPP, the cancer incidence and the number of population. Economically country classification is determining with the Gross national income (GNI), per capita, Purchasing power parity (PPP), according the administrations of the International Monetary Fund (IMF), the World Bank (WB) and the Central Intelligence Agency (CIA). Cancer incidence data presented are based on the most recent data available at IARC. However, population compares estimates from the US Bureau of the Census. The provisional budget is establishing among the guidelines developed by WHO for regional and national cancer control programs according to national economic development. Provisional budget against cancer is estimated to 9,169.203 (thousands of U.S $) for a population of 11,031,386 persons in Somalia.

Worldwide, one in eight deaths is due to cancer. Projections based on the GLOBOCAN 2012 estimates predict a substantive increase new cancer cases per year by 2035 in developing countries if preventive measures are not widely applied. According to the World Health Organization (WHO), millions of lives could be saved each year if countries made use of existing knowledge and the best cost-effective methods to prevent and treat cancer. Therefore, the aim of this study is to estimate a provisional budget against cancer in low and middle incomes countries, according the GNI-PPP, the cancer incidence and the number of population. Economically country classification is determining with the Gross national income (GNI), per capita, Purchasing power parity (PPP), according the administrations of the International Monetary Fund (IMF), the World Bank (WB) and the Central Intelligence Agency (CIA). Cancer incidence data presented are based on the most recent data available at IARC. However, population compares estimates from the US Bureau of the Census. The provisional budget is establishing among the guidelines developed by WHO for regional and national cancer control programs according to national economic development. Provisional budget against cancer is estimated to 71,973.042 (thousands of U.S $) for a population of 13,026,129 persons in South Sudan